Stock Details
MRK.DE is MERCK Kommanditgesellschaft auf Aktien's stock. Stock exchange XETRA (Currency EUR). Average price in 50 days is 175.44โ‚ฌ. Average daily volumn in 3 months 244.97k. Market cap 75.54B

Stock symbol : MRK.DE. Exchange : XETRA. Currency : EUR
Lastest price : 173.75โ‚ฌ. Total volume : 264.01k. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

MERCK Kommanditgesellschaft auf Aktien (MRK.DE)
Last Price

Previous Close168.00
Day Range168.95-173.90
Bid173.20 x 6.7k
Ask173.20 x 11.2k
Average Volume244.97k
Market Cap75.54B
52 Week Range153.10-231.50
Trailing P/E22.80
Foward P/E16.01
Dividend (Yield %)1.11%
Ex-Dividend Date2022-04-25

Financial Details

According to MERCK Kommanditgesellschaft auf Aktien's financial reports the company's revenue in 2021 were 19.69B an increase( +11.76%) over the years 2020 revenue that were of 17.53B. In 2021 the company's total earnings were 3.06B while total earnings in 2020 were 1.99B( +200%).

Loading ...


MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers materi... al for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Market Cap:
Total Assets:
Total Cash:

News about "MERCK Kommanditgesellschaft auf Aktien"

MKKGY MERCK Kommanditgesellschaft auf Aktien

Source from : Seeking Alpha - 12 days ago

**NM signifies a non meaningful value. A dash signifies the data is not available.See details»

MERCK Kommanditgesellschaft auf Aktien (MRCK.VI)

Source from : Yahoo Finance - 12 days ago

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...See details»

MERCK Kommanditgesellschaft auf Aktien: Merck KGaA Turns In Strong Q2 Including Currency Rate Benefits; No Change to Fair Value Estimate

Source from : YAHOO!Finance - 15 days ago

Find the latest MERCK KGAA SPON ADR EACH REPR 0 (MKKGY) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...See details»

Merck Aktie News: Merck reagiert am Nachmittag positiv

Source from : Finanzen - 4 days ago

Zu den bestplatzierten Aktien des Tages zรคhlt am Freitagnachmittag der Anteilsschein von Merck. Die Aktie legte zuletzt in der XETRA-Sitzung 1,3 Prozent auf 165,75 EUR zu. Im XETRA-Handel ...See details»

Merck Aktie News: Merck am Donnerstagnachmittag gefragt

Source from : Finanzen - 5 days ago

Zuletzt stieg die Merck-Aktie. In der XETRA-Sitzung kletterte das Papier um 0,6 Prozent auf 163,60 EUR. Die Merck-Aktie stieg im XETRA-Handel. Um 04:22 Uhr verteuerte sich das Papier um 0,6 ...See details»

4MRK : What Are Whales Doing With Merck & Co

Source from : - 20 days ago

Someone with a lot of money to spend has taken a bullish stance on Merck & Co MRK. And retail traders should know. We noticed this today when the big position showed up on publicly available ...See details»

Berenberg upgrades Merck to buy, says it's a solid 'low-risk option' in pharma

Source from : CNBC - 20 days ago

Merck has a lot to offer investors looking for low-risk buys in the pharmaceutical sector, according to Berenberg. The firm on Tuesday upgraded shares of the company to buy from hold and raised ...See details»

Analyst Ratings for Merck & Co

Source from : Business Insider - 22 days ago

Analysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter: These 9 analysts have an average price target of $100.78 versus the current price of Merck & Co at $ ...See details»

Merck's Deal With Seagen May Have Fallen Through. Now What?

Source from : The Motley Fool - 27 days ago

After months of buyout rumors, talks seem to have stalled on pricing. Seagen's technology could strengthen Merck's pipeline but brings plenty of risk. Merck has one of the premier oncology ...See details»

5MRK : This Is What Whales Are Betting On Merck & Co

Source from : - 22 days ago

A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co MRK we detected 17 strange trades. If we consider the specifics ...See details»

Key Factors Driving Merck's (MRK) Outperformance This Year

Source from : Nasdaq - 20 days ago

Merckโ€™s MRK stock has risen 12.6% this year so far against a decrease of 1.3% for the industry. Merckโ€™s first-half results were strong as it beat estimates for both earnings and sales in the ...See details»

Merck To Begin Phase 3 Program With Lower Dose Of Islatravir With Doravirine

Source from : Business Insider - 14 days ago

(RTTNews) - Merck (MRK) said it will initiate a phase 3 clinical program with once-daily islatravir for the treatment of people with HIV-1 infection. The new phase 3 studies will evaluate a once ...See details»

Merck, Johnson & Johnson share losses lead Dow's nearly 50-point fall

Source from : MarketWatch - 15 days ago

Shares of Merck and Johnson & Johnson are posting losses Monday morning, dragging the Dow Jones Industrial Average into negative territory. Shares of Merck MRK, -2.01% and Johnson & Johnson JNJ ...See details»

Merck elevates George Addona into discovery role

Source from : MM&M - 20 days ago

Merck has appointed George Addona as SVP and head of discovery, preclinical and translational medicine at Merck Research Laboratories. Addona originally joined Merck in 2008 and has held various roles ...See details»